Clinical trials: Plaque Psoriasis.
Psoriasis
A Study Comparing the Safety and Efficacy of Risankizumab to Methotrexate in Subjects With Moderate to Severe Plaque Psoriasis
The purpose of this study is to compare the safety and efficacy of risankizumab to methotrexate in participants with moderate to severe plaque psoriasis.
- Trial name
- NCT03219437
- Testing
- risankizumab, methotrexate
- Where
- 11 sites in Brazil
- Volunteers
- 104 people
- Sponsor
- AbbVie
Plaque Psoriasis
ORKA-001 Versus Placebo in Patients With Moderate-to-Severe Plaque Psoriasis
This is a multicenter, randomized, double-blinded, placebo-controlled, proof-of-concept study to evaluate the efficacy, safety, tolerability, and pharmacokinetics of ORKA-001 in adult participants with moderate-to-severe plaque…
- Trial name
- EVERLAST-A (NCT07090330)
- Testing
- ORKA-001 Induction Dose, ORKA-001 Maintenance Dose
- Where
- 26 sites in United States, Canada
- Volunteers
- 80 people
- Sponsor
- Oruka Therapeutics, Inc.
Plaque Psoriasis
Study Evaluating Single Dose Of ILV-095 In Psoriasis Subjects
The purpose of this research study is to evaluate the safety and tolerability of ILV-095 when it is given to individuals with moderate to severe chronic plaque psoriasis.
- Trial name
- NCT01010542
- Testing
- ILV-095 300 mg in a 4 to 1 ratio
- Where
- 9 sites in United States, Canada
- Volunteers
- 39 people
- Sponsor
- Pfizer
Psoriasis
A Registry of Patients With Moderate to Severe Plaque Psoriasis
The main purpose of the current study will be to provide real - world evidence regarding the safety and effectiveness of secukinumab in the management of patients with moderate to severe chronic plaque psoriasis.
- Trial name
- PURE (NCT02786186)
- Testing
- Secikinumab
- Where
- 13 sites in Canada
- Volunteers
- 2,376 people
- Sponsor
- Novartis Pharmaceuticals
Moderate and Severe Plaque Psoriasis
Safety and Efficacy of UC-MSCs in Patients With Plaque Psoriasis
This is a study in patients with moderate to severe chronic plaque psoriasis.All the participants will be randomized into three groups, high-dose UC-MSCs, low-dose UC-MSCs, or methotrexate group.This study is designed to prove…
- Trial name
- NCT03424629
- Testing
- Low-dose UC-MSCs, High-dose UC-MSCs, Methotrexate
- Where
- 2 sites in China
- Volunteers
- 57 people
- Sponsor
- Tianjin Ever Union Biotechnology Co., Ltd.
Chronic Plaque Psoriasis
Phase II Efficacy Study Looking at a Single-dose of One of Three Dose Levels of AIN457 in Patients With Chronic Plaque-type Psoriasis
This is an exploratory, 4 arm, parallel group, placebo-controlled study comparing three doses of AIN457 to placebo. Subjects with a diagnosis of moderate to severe chronic plaque psoriasis will be randomized to receive either…
- Trial name
- NCT00770965
- Testing
- AIN457
- Where
- 5 sites in United States
- Volunteers
- 80 people
- Sponsor
- Novartis Pharmaceuticals
Psoriasis
A Study to Evaluate Safety and Efficacy of Infliximab in Chinese Participants With Moderate to Severe Plaque-type Psoriasis
The purpose of this study is to determine the superiority and efficacy of infliximab induction therapy in chinese participants with moderate to severe plaque-type psoriasis (scaly skin rash) compared with placebo (an inactive…
- Trial name
- NCT01177800
- Testing
- Infliximab
- Where
- 7 sites in China
- Volunteers
- 129 people
- Sponsor
- Xian-Janssen Pharmaceutical Ltd.
Plaque Psoriasis
A Observational Study to Evaluate Deucravacitinib in Patients With Moderate Plaque Psoriasis in China
The purpose of this study is to collect and evaluate real-world data on the effectiveness of deucravacitinib treatment in adults with moderate plaque psoriasis in China.
- Trial name
- ADMIRE (NCT06512337)
- Testing
- Deucravacitinib
- Where
- 5 sites in China
- Volunteers
- 153 people
- Sponsor
- Bristol-Myers Squibb
Psoriasis
A Safety and Pharmacokinetics Study of IDP-122 Lotion in Pediatric Participants With Plaque Psoriasis
This study is to evaluate the safety, the systemic exposure of halobetasol propionate (HP), and the hypothalamic-pituitary-adrenal (HPA) axis suppression potential for topically applied IDP-122 lotion in pediatric participants…
- Trial name
- NCT03987763
- Testing
- IDP-122 Lotion
- Where
- 9 sites in United States, Dominican Republic and 1 more
- Volunteers
- 45 people
- Sponsor
- Bausch Health Americas, Inc.
Psoriasis
Assessment of Efficacy and Safety of Secukinumab in Adult Patients in Turkish Population
Secukinumab targets a different interleukin and has potential to be used as alternative to existing treatments. This study will provide clinical data with respect to efficacy through Psoriasis Area and Severity Index (PASI) at 16…
- Trial name
- NCT02795416
- Testing
- "Secukinumab" "Cosentyx TM"
- Sponsor
- Novartis Pharmaceuticals
Plaque Psoriasis
A Phase 3 Clinical Study of QL2106 Injection
It is a multicenter randomized, double-blinded, parallel, positive-controlled, Phase 3 comparative study to evaluate the efficacy and safety of QL2106 injection to Tremfya® in Patients with Moderate to Severe Plaque Psoriasis.
- Trial name
- NCT07511647
- Testing
- QL2106 injection, Tremfya®
- Where
- China
- Volunteers
- 318 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Plaque Psoriasis
A 16-week Randomized Evaluation of the Impact of Mind.Px Application on Response to Biologic Treatment in Patients Suffering From Plaque Psoriasis Through Clinical Utility and Health Outcomes.
This protocol describes randomized, multicenter, blinded (subjects), 16-week, controlled study in parallel balanced groups of psoriasis (Ps) patients to evaluate the impact of Mind.Px on response to biologic treatments.
- Trial name
- MATCH (NCT05036889)
- Testing
- Mind.Px Report
- Volunteers
- 200 people
- Sponsor
- Mindera Health
Psoriasis
A Study to Assess Safety and Efficacy of Risankizumab Using a New Formulation in Participants With Moderate to Severe Plaque Psoriasis
The primary objective of this study was to evaluate the safety and efficacy of risankizumab (150 mg/mL) administered by prefilled syringe (PFS) for the treatment of adult participants with moderate to severe plaque psoriasis.
- Trial name
- NCT03875482
- Testing
- Risankizumab
- Where
- 43 sites in United States, Puerto Rico
- Volunteers
- 157 people
- Sponsor
- AbbVie
Chronic Plaque Psoriasis
Multiple-loading Dose Regimen Study in Patients With Chronic Plaque-type Psoriasis
Loading dose, four arm, double-blind, parallel group, placebo-controlled study comparing single and multiple doses of AIN457 to placebo in patients with a diagnosis of moderate to severe chronic plaque psoriasis.
- Trial name
- NCT00805480
- Testing
- AIN457
- Volunteers
- 130 people
- Sponsor
- Novartis Pharmaceuticals
Plaque Psoriasis
Safety and Efficacy of IDP-122 in Participants With Plaque Psoriasis
This study is to evaluate the safety and efficacy of a topical lotion when applied once daily to adult participants with moderate to severe plaque psoriasis (defined as an Investigator's Global Assessment [IGA] score of 3 or 4).
- Trial name
- NCT02515097
- Testing
- IDP-122 Lotion, IDP-122 Vehicle Lotion
- Where
- 15 sites in United States
- Volunteers
- 213 people
- Sponsor
- Bausch Health Americas, Inc.
Plaque Psoriasis
Characteristics of Patients Treated With Secukinumab for Moderate to Severe Plaque Psoriasis
This study was a non-interventional, retrospective study collecting data from hospital medical records. Approximately 200 adult patients with moderate to severe plaque psoriasis who were treated with secukinumab from hospitals in…
- Trial name
- NCT05650060
- Testing
- Secukinumab
- Where
- Thailand
- Volunteers
- 163 people
- Sponsor
- Novartis Pharmaceuticals
Psoriasis, Psoriatic Arthritis
Study to Assess the Safety and Change in Disease Symptoms of Risankizumab (Skyrizi) in Adult Participants With Moderate to Severe Plaque Psoriasis and Psoriatic Arthritis
Plaque Psoriasis is a chronic inflammatory disease in which skin cells build up and develop scaly red and white patches on the skin.
- Trial name
- NCT04433442
- Where
- 63 sites in South Korea
- Volunteers
- 2,324 people
- Sponsor
- AbbVie
Psoriasis
A Study to Evaluate Raptiva in Adults With Moderate to Severe Plaque Psoriasis Who Are Candidates for Systemic Therapy
This is a Phase IIIb, randomized, double-blind, parallel-group, placebo-controlled, multicenter study designed to evaluate the safety and tolerability of efalizumab administered subcutaneously at weekly doses of 1.0 mg/kg in…
- Trial name
- NCT00109317
- Testing
- Raptiva (efalizumab)
- Volunteers
- 686 people
- Sponsor
- Genentech, Inc.
Psoriasis, Plaque Type Psoriasis
MSB11022 in Moderate to Severe Chronic Plaque Psoriasis
The purpose of this study was to compare the efficacy, safety and immunogenicity of MSB11022 and Humira® in adult subjects with moderate to severe chronic plaque type psoriasis.
- Conditions
- Psoriasis, Plaque Type Psoriasis, Moderate to Severe Plaque Psoriasis
- Trial name
- AURIEL-PsO (NCT02660580)
- Testing
- MSB11022, Humira®
- Where
- 76 sites in United States, Bulgaria and 10 more
- Volunteers
- 443 people
- Sponsor
- Fresenius Kabi SwissBioSim GmbH
Plaque Psoriasis
The Efficacy and Safety of TLL018 in Moderate-to-severe Plaque Psoriasis
This is a Phase 2, multicenter, randomized, double-blinded, parallel dose group, placebo-controlled, dose-ranging study to evaluate the efficacy and safety of 2 doses of TLL018 as therapy in approximately 90 participants with…
- Trial name
- NCT05772520
- Testing
- TLL018 tablets
- Where
- 35 sites in United States
- Volunteers
- 82 people
- Sponsor
- Hangzhou Highlightll Pharmaceutical Co., Ltd